Paul is the CEO & Co-founder of Locus Biosciences. With a career that spans manufacturing, research & development, information technology and corporate transformations, Paul brings a broad range of experience and capability to deliver on the Locus vision. Prior to Locus, Paul was Chief Technology Officer at Patheon Pharmaceuticals and also held the role of Global Head of Operations for Patheon’s Pharmaceuticals Development Services business unit.
Read MoreDr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therapeutics and diagnostics, including a novel class of affordable, effective, and rapid CRISPR-enabled molecular diagnostics that allow individuals worldwide to better understand their health and a novel family of CRISPR Cas14 proteins that can enable in vivo editing.
Read MoreLaurence joined Decibel in January 2020. He previously served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug discovery and development opportunities. Before that, Laurence was CEO of Warp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products, until its merger with Revolution Medicines in 2018.
Read MoreMs. Zaderej has served as Axogen’s President, Chief Executive Officer, and a member of our Board of Directors since September 2011 and the Chairman of our Board of Directors since May 2018. Since May 2010, she has served as the Chief Executive Officer of Axogen’s wholly owned subsidiary, Axogen Corporation, and a member of the Board of Directors of Axogen Corporation.
Read MoreJohn Glasspool is CEO and member of the Board of Directors of Anthos Therapeutics. Mr. Glasspool is also a member of the Board of Directors of Dalcor Corporation. He was formerly the Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta Incorporated (NYSE: BXLT), formerly Baxter BioScience (NYSE: BAX).
Prior to joining Baxter in August 2012, Mr. Glasspool was Head of Region Europe and Novartis Vaccines & Diagnostics (NYSE: NVS), a member of the V&D Executive Committee. Mr. Glasspool served as a board member, Vice President and President of the European Vaccine manufacturers (EVM), from 2010 until December 2012.
Dr. Sullivan is co-founder and CEO of Vanqua. In addition, he has been a Venture Partner with Orbimed since January 2019. Previously, he was the Vice President of Research at Abbvie where he was responsible for the company’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C and cystic fibrosis. Jim has advanced more than 100 compounds into clinical development across a number of disease states and technology platforms.
Read MorePaula Soteropoulos brings to Ensoma more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization with P&L accountability, company building and organizational development. Her leadership throughout her career spans a broad range of therapeutic areas, including rare disease, cardiovascular and metabolism, infectious disease, renal, and transplant and oncology. In addition to Ensoma, Paula is a strategic advisor to 5AM Ventures and a member of the Board of Directors of uniQure and Rallybio.
Read MoreJake Becraft is co-founder and CEO of Strand Therapeutics, an emerging biotechnology company at the forefront of mRNA therapeutics.
Lex Rovner is the CEO and cofounder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute at Harvard University.
Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners.
Nabiha Saklayen is CEO & co-founder of Cellino. Cellino’s proprietary technology makes personalized stem cell-derived therapies scalable for the first time.
Read MoreTim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix. Tim has extensive experience in medical practice (general & trauma surgery), bench research, and bioinformatics / machine learning. While training at Stanford he helped invent the core technology on which Inflammatix is based, is named on over a dozen patents related to medical diagnostics, and has published >100 manuscripts & abstracts.
Read MoreAl leads teams in early-stage discovery up through non-clinical development, identifying new drug candidates for advancement into clinical research. Al joined Sage as CSO in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation.
Read MoreDr. Stuart Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the Board of Directors since the company’s inception.
Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. PTC now has a footprint in more than 50 countries, with offices in 20 countries and more than 1,000 employees.
Patrick Kleyn joined Rhythm in 2018 with over 25 years’ experience in human genetics and genomics, and he was named as head of TRAD in 2021. Prior to joining Rhythm, Patrick has held leadership roles in academia, biotech and large pharmaceutical companies, as his work has focused on the application of genomic technologies for drug and biomarker discovery and development. He began his career at Millennium Pharmaceuticals initially working on obesity target discovery and ultimately leading the genomics organization.
Read More
